Article

Development and validation of multivariate predictors of primary endocrine resistance to tamoxifen and aromatase inhibitors in luminal breast cancer reveal drug-specific differences

2023-11-13

Abstract excerpt

<h4>Background</h4> Endocrine therapy is highly effective in blocking the estrogen receptor pathway in HR+/HER2– early breast cancer (EBC). However, up to 40% of patients experience relapse during or after adjuvant endocrine therapy. Here, we investigate molecular mechanisms associated with primary resistance to endocrine therapy and develop predictive models. <h4>Patients and Methods</h4> In the WSG-ADAPT trial (...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: b2809554-311e-558a-b33a-23b37c43c3a9
DOI: 10.1101/2023.11.13.23298466

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Development and validation of multivariate predictors of primary endocrine resistance to tamoxifen and aromatase inhibitors in luminal breast cancer reveal drug-specific differencesDOI 10.1101/2023.11.13.23298466Read

A predictive endocrine resistance index accurately stratifies luminal breast cancer treatment responders and nonresponders.Semantic proximity Read

Candidate methylation sites associated with endocrine therapy resistance in ER+/HER2- breast cancerSemantic proximity Read

Candidate methylation sites associated with endocrine therapy resistance in the TCGA ER+/HER2- breast cancer cohortSemantic proximity Read

Integrated DNA and RNA Sequencing Reveals Drivers of Endocrine Resistance in Estrogen Receptor–Positive Breast CancerSemantic proximity Read

Molecular profiling of aromatase inhibitor sensitive and resistant ER+HER2- postmenopausal breast cancersSemantic proximity Read

TP53 mutations are associated with primary endocrine resistance in luminal early breast cancer.Semantic proximity Read

Decoding breast cancer treatment resistance through genetic, epigenetic, and immune-regulatory mechanisms: from molecular insights to translational perspectivesSemantic proximity Read

Integrative analysis of pre-treatment RNA expression signatures and recurrent genomic alterations: Link to menopausal status, short-term endocrine therapy response and disease-free survival in luminal breast cancerSemantic proximity Read

Genomic hallmarks of endocrine therapy resistance in ER/PR+HER2- breast tumoursSemantic proximity Read

Endocrine resistance in hormone-responsive breast cancer: mechanisms and therapeutic strategies.Semantic proximity Read

Endocrine therapy-specific lineage and partial epithelial-mesenchymal reprogramming defines divergent resistant cell-states in ER+ breast cancerSemantic proximity Read

Metastatic ER+ Breast Cancer: Mechanisms of Resistance and Future Therapeutic ApproachesSemantic proximity Read